A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer
Status:
Suspended
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This open-label, one-center, noncomparative, two-stages phase 1B trial assessed the tyrosine
kinase inhibitor donafenib tosylate tablets(400 mg/d,200mg bid) in patients with advanced,
inoperable oesophageal cancer progressing after chemotherapy .
The primary endpoint is the safety.The secondary endpoints are tumor response and
progression-free survival.